Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A cost-effectiveness analysis

References

• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76
   PubMed Web of Science ®Google Scholar
• Barlev A, Song X, Ivanov B, et al. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010;16:693-702
   PubMed Web of Science ®Google Scholar
• Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006. Prostate Cancer Prostatic Dis 2011;14:177-83
   PubMed Web of Science ®Google Scholar
• Bouganim N, Clemons MJ. Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block? Future Oncol 2011;7:381-3
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22
   PubMed Web of Science ®Google Scholar
• Amgen. FDA Approves Amgen’s XGEVA(TM) (Denosumab) for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Amgen Press Release 2010. URL:http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1498709. Accessed 9 March 2012
   Google Scholar
• Drug Topics Red Book. Montvale, NJ: Thomson Healthcare; 2010
   Google Scholar
• Aapro MS. Denosumab for bone metastases from breast cancer: a new therapy option? J Clin Oncol 2011;29(14):e419-20
   Web of Science ®Google Scholar
• Aragon-Ching JB. Unravelling the role of denosumab in prostate cancer. Lancet 2011;377:785-6
   PubMed Web of Science ®Google Scholar
• West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol 2011;29:1095-8
   PubMed Web of Science ®Google Scholar
• Wahed AS, Luong TM, Jeong JH. A new generalization of Weibull distribution with application to a breast cancer data set. Stat Med 2009;28:2077-94
   PubMed Web of Science ®Google Scholar
• Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the “DEALE”). I. Validation of the method. Am J Med 1982;73:883-8
   PubMed Web of Science ®Google Scholar
• Reed SD, Radeva JI, Glendenning GA, et al. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol 2004;171:1537-42
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84
   PubMed Web of Science ®Google Scholar
• Ford J, Cummins E, Sharma P, et al. Systematic review of the clinical effectiveness and cost effectiveness and economic evaluation of denosumab for the treatment of bone metastases from solid tumors. Aberdeen: Aberdeen HTA Group, Institure of Applied Sciences, University of Aberdeen, 2011
   Google Scholar
• Denosumab [Package Insert]. Thousand Oaks, CA: Amgen Incorporated, 2010
   Google Scholar
• Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68
   PubMed Web of Science ®Google Scholar
• Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-84
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Carter JA, Kaura S, et al. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer. Clin Ther 2012;34(6):1334-49
   PubMed Web of Science ®Google Scholar
• Barlev A, Chung K, Delea T, et al. Healthcare and utilization costs associated with skeletal related events in prostate cancer patients with bone metastases. J Manag Care Pharm 2010;16(9):693-702
   Google Scholar
• National Fee Analyzer. Eden Prairie, MN: Ingenix Inc, 2011
   Google Scholar
• Neighbors DM, Bell TJ, Wilson J, et al. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage 2001;21:129-43
   PubMed Web of Science ®Google Scholar
• Moore S, Tumeh J, Wojtanowski S, et al. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health 2007;10:23-31
   PubMed Web of Science ®Google Scholar
• Klarenbach S, Manns B, Reiman T, et al. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer. Cancer 2010;116:3224-32
   PubMed Web of Science ®Google Scholar
• Greenberg D, Earle C, Fang CH, et al. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 2010;102:82-8
   PubMed Web of Science ®Google Scholar
• Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-5
   PubMed Web of Science ®Google Scholar
• Hillner BE, Weeks JC, Desch CE, et al. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000;18:72-9
   PubMed Web of Science ®Google Scholar
• Sartor O. Denosumab in bone-metastatic prostate cancer: known effects on skeletal-related events but unknown effects on quality of life. Asian J Androl 2011;13:612-3
   PubMed Web of Science ®Google Scholar
• Carter JA, Botteman MF. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer. Expert Rev Pharmacoecon Outcomes Res 2012preprint [Epub ahead of print]
   Google Scholar
• Stopeck A, Rader M, Henry D, et al. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ 2012;15(4):712-23
   PubMedGoogle Scholar
• Lothgren M, Bracco A, Lucius B, et al. Cost-Effectiveness of denosumab vs zoledronic acid (ZA) for the prevention of skeletal-related events (SRE) in patients with bone metastases from solid tumors in the Netherlands. International Society for Pharmacoeconomics and Outcomes Research 14th Annual European Congress in Madrid, Spain. 2011
   Google Scholar
• Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008;113:1438-45
   PubMed Web of Science ®Google Scholar
• Hatoum HT, Lin SJ, Guo A, et al. Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin 2011;27:55-62
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32
   PubMed Web of Science ®Google Scholar